Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD).

The Viela deal will add to Horizon's commercial rare disease medicine portfolio in the form of Uplinza, which has been approved by the FDA for treating neuromyelitis optica spectrum disorder.

There was also a change in the Quantitative Myasthenia Gravis (QMG) score, with 69.2% of AChR+ patients in the Uplinza group ...

Both were acquired with Amgen's 2023 purchase of Horizon Therapeutics. Sales of rare disease drug Uplinza rose 14% to $91 million. Amgen said the FDA has accepted its application seeking approval ...

“Additional pipeline assets, including Imdelltra and rocatinlimab, also have blockbuster potential, and we believe additional Phase 3 readouts with Uplinza expected in the second half of this ...